Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jun;61(6):877–880. doi: 10.1038/bjc.1990.196

Does the oestrogen receptor concentration of a breast cancer change during systemic therapy?

R A Hawkins 1, A L Tesdale 1, E D Anderson 1, P A Levack 1, U Chetty 1, A P Forrest 1
PMCID: PMC1971691  PMID: 2372489

Abstract

The effect of systemic therapy on tumour oestrogen receptor (ER) concentration has been studied in 88 patients with large, operable, primary tumours (total 89) of the breast. In 26 patients, tumour was not available for study on one occasion (usually post-treatment). Forty-five patients were treated initially by endocrine therapy but, of these, 13 who had failed to respond went on to receive chemotherapy also. Seventeen patients with low concentrations of ER (less than 20 fmol mg-1 protein) were treated directly by chemotherapy. Patients underwent an incisional biopsy for confirmation of diagnosis and determination of pre-treatment ER by radioligand binding assay, followed by systemic therapy for 3 months (or 6 months for both endocrine and cytotoxic therapies). Response was assessed clinically and mammographically before mastectomy. ER concentration was then determined in the post-treatment tumour specimen. No significant change in ER concentration was seen in any treatment group except when the patients had received tamoxifen; there, receptor concentration fell to very low levels, presumably due to interference with the assay. There was no relationship between tumour response to systemic treatment and change in ER concentration. It is concluded that changes in ER concentration are unlikely to play a major role in the early response of breast tumours to systemic therapy.

Full text

PDF
877

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson E. D., Forrest A. P., Levack P. A., Chetty U., Hawkins R. A. Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer. Br J Cancer. 1989 Aug;60(2):223–226. doi: 10.1038/bjc.1989.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  3. Cho-Chung Y. S., Bodwin J. S., Clair T. Cyclic AMP-binding proteins: inverse relationship with estrogen-receptors in hormone-dependent mammary tumor regression. Eur J Biochem. 1978 May;86(1):51–60. doi: 10.1111/j.1432-1033.1978.tb12283.x. [DOI] [PubMed] [Google Scholar]
  4. Forrest A. P., Levack P. A., Chetty U., Hawkins R. A., Miller W. R., Smyth J. F., Anderson T. J. A human tumour model. Lancet. 1986 Oct 11;2(8511):840–842. doi: 10.1016/s0140-6736(86)92872-2. [DOI] [PubMed] [Google Scholar]
  5. Hawkins R. A., Black R., Steele R. J., Dixon J. M., Forrest A. P. Oestrogen receptor concentration in primary breast cancer and axillary node metastases. Breast Cancer Res Treat. 1981;1(3):245–251. doi: 10.1007/BF01806264. [DOI] [PubMed] [Google Scholar]
  6. Hawkins R. A., Hill A., Freedman B. A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues. Clin Chim Acta. 1975 Oct 15;64(2):203–210. doi: 10.1016/0009-8981(75)90202-8. [DOI] [PubMed] [Google Scholar]
  7. Hawkins R. A., Hill A., Freedman B., Gore S. M., Roberts M. M., Forrest A. P. Reproducibility of measurements of oestrogen-receptor concentration in breast cancer. Br J Cancer. 1977 Sep;36(3):355–361. doi: 10.1038/bjc.1977.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hoehn J. L., Plotka E. D., Dickson K. B. Comparison of estrogen receptor levels in primary and regional metastatic carcinoma of the breast. Ann Surg. 1979 Jul;190(1):69–71. doi: 10.1097/00000658-197907000-00015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hull D. F., 3rd, Clark G. M., Osborne C. K., Chamness G. C., Knight W. A., 3rd, McGuire W. L. Multiple estrogen receptor assays in human breast cancer. Cancer Res. 1983 Jan;43(1):413–416. [PubMed] [Google Scholar]
  10. Lumsden M. A., West C. P., Hawkins R. A., Bramley T. A., Rumgay L., Baird D. T. The binding of steroids to myometrium and leiomyomata (fibroids) in women treated with the gonadotrophin-releasing hormone agonist Zoladex (ICI 118630). J Endocrinol. 1989 May;121(2):389–396. doi: 10.1677/joe.0.1210389. [DOI] [PubMed] [Google Scholar]
  11. Mobbs B. G., Fish E. B., Pritchard K. I., Oldfield G., Hanna W. H. Estrogen and progesterone receptor content of primary and secondary breast carcinoma: influence of time and treatment. Eur J Cancer Clin Oncol. 1987 Jun;23(6):819–826. doi: 10.1016/0277-5379(87)90285-9. [DOI] [PubMed] [Google Scholar]
  12. Senbanjo R. O., Miller W. R., Hawkins R. A. Variations in steroid receptors and cyclic AMP binding proteins across human breast cancers: evidence for heterogeneity. Br J Cancer. 1986 Jul;54(1):127–130. doi: 10.1038/bjc.1986.162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Vignon F., Rochefort H. Regulation of estrogen receptors in ovarian-dependent rat mammary tumors. I. Effects of castration and prolactin. Endocrinology. 1976 Mar;98(3):722–729. doi: 10.1210/endo-98-3-722. [DOI] [PubMed] [Google Scholar]
  14. van Netten J. P., Algard F. T., Coy P., Carlyle S. J., Brigden M. L., Thornton K. R., Peter S., Fraser T., To M. P. Heterogeneous estrogen receptor levels detected via multiple microsamples from individual breast cancers. Cancer. 1985 Oct 15;56(8):2019–2024. doi: 10.1002/1097-0142(19851015)56:8<2019::aid-cncr2820560822>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES